USPTO Examiner NGUYEN JOHN P - Art Unit 1619

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18643595TOPICAL PHARMACEUTICAL COMPOSITIONSApril 2024August 2024Allow410NoNo
18607763FISH-DERIVED PEPTIDOGLYCAN RECOGNITION PROTEIN MUTANTAND APPLICATION THEREOFMarch 2024August 2024Allow510NoNo
18583657METHODS FOR RAISING NITRIC OXIDE AND REDUCTION OF URIC ACIDFebruary 2024March 2025Abandon1320NoNo
18386411ETHYL 2-[9-(6-FLOURO-2-HYDROXYQUINOLIN-3-YL)-1,8-DIOXO-3,4,9,10-TETRAHYDROACRIDINE-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUNDNovember 2023February 2024Allow300NoNo
18242099Micronutrient composition to improve men healthSeptember 2023March 2024Allow610YesNo
18448754FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEMAugust 2023August 2024Abandon1220YesNo
18448640FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEMAugust 2023February 2025Abandon1830YesNo
18172403ANTI-INFECTION AND ANTI-TUMOR MUCOSAL IMMUNE PREPARATIONFebruary 2023January 2025Abandon2301NoNo
18162259MICROPARTICLES CONTAINING BUPROPIONJanuary 2023February 2024Abandon1320YesNo
18098361SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONSJanuary 2023November 2024Allow2210NoNo
17995021Use of an arsenic compound for treating a short or long cytokine storm in various autoimmune/inflammatory diseases in humans or animalsSeptember 2022May 2025Abandon3201NoNo
17847951TYROSINE DERIVATIVES AND COMPOSITIONS COMPRISING THEMJune 2022October 2024Abandon2801NoNo
17835805METHOD OF TREATING MIGRAINES AND HEADACHESJune 2022August 2023Allow1430YesNo
17731403COMPOSITIONS AND METHODS FOR REDUCING AT LEAST ONE SYMPTOM OF HUMAN ALLERGY TO CATSApril 2022April 2024Allow2420YesNo
17725189SOTALOL HYDROCHLORIDE DOSINGApril 2022April 2025Allow3610NoNo
17671540PHARMACEUTICAL FORMULATIONS OF NITRITE AND USES THEREOFFebruary 2022September 2024Abandon3110NoNo
17579914FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEMJanuary 2022September 2023Allow2030NoNo
17646935USE OF FRUCTOSE IN PREPARING DRUG FOR TREATING ISCHEMIC INJURYJanuary 2022December 2023Allow2320NoNo
17560423FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEMDecember 2021June 2022Allow620YesNo
17560392FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEMDecember 2021June 2022Allow620YesNo
17552193MOLECULAR HYDROGEN-CONTAINING COMPOSITION FOR MAINTAINING LUNG FUNCTION IN HUMAN LUNG CANCER AND/OR IMPROVING REDUCTION IN LUNG FUNCTION ATTRIBUTED TO HUMAN LUNG CANCERDecember 2021March 2024Abandon2720NoNo
17541533METHODS AND COMPOSITIONS FOR TREATING HEART CONDITIONSDecember 2021July 2024Allow3220YesNo
17539595COMPOSITIONS, DEVICES, AND METHODS FOR TREATING RESPIRATORY DISORDERSDecember 2021March 2023Abandon1641YesYes
17537635PROCESS FOR THE PREPARATION OF A READY-TO-USE, COSMETIC, FLOWABLE DETERGENTNovember 2021July 2024Allow3211NoNo
17527401COMPOSITION AND METHOD FOR TREATMENT OF DIABETESNovember 2021June 2025Abandon4311NoNo
17525841METHODS OF INCREASING BLOOD OXYGEN SATURATIONNovember 2021July 2024Allow3241YesNo
17520323SYSTEM FOR PROVIDING BIRTH CONTROLNovember 2021January 2025Allow3820YesNo
17507957Electronic Device SanitizerOctober 2021December 2023Abandon2610NoNo
17507170ANTIMICROBIAL GUANIDINIUM MACROMOLECULES WITH BACTERIA TARGETING MOIETIESOctober 2021April 2024Allow3020YesNo
17500075Permeable and Semi Permeable Substrate and SubstanceOctober 2021May 2024Allow3120NoNo
17496351METHODS FOR PROVIDING THE BENEFITS OF METHIONINE RESTRICTION WITHOUT DIETARY RESTRICTIONOctober 2021March 2025Abandon4121NoNo
17492451COMPOSITION FOR PREVENTING AND TREATING MICROBIAL DISEASEOctober 2021May 2024Abandon3221YesNo
17485686DRUG DELIVERY SYSTEM WITH ENHANCED IMMUNE ACTIVE FUNCTIONSeptember 2021March 2025Allow4231NoNo
17468481PROTECTION OF MICROBIAL CELLS FROM ACIDIC DEGRADATIONSeptember 2021October 2023Allow2501YesNo
17466974MINERAL CATION COMPLEX COMPOSITIONS, FORMULATIONS THEROF, AND METHODS OF USE THEROFSeptember 2021December 2022Allow1531NoNo
17411295ANTIBACTERIAL SURFACE TREATED COPPER MATERIAL AND A METHOD FOR PREPARING THE SAMEAugust 2021March 2023Allow1900NoNo
17392507CHLORINE DIOXIDE SUSTAINED-RELEASING DISINFECTING NANO MATERIAL AND PREPARATION METHOD AND USE THEREOFAugust 2021October 2023Abandon2610NoNo
17379255MULTI-NUTRIENT SUPPLEMENT COMPOSITION AND USES THEREOFJuly 2021December 2023Allow2910NoNo
17375349SANITIZING AND ODOR ELIMINATION COMPOSITION AND METHOD OF MAKING THE SAMEJuly 2021October 2024Abandon4020NoNo
17340343THREE-PART MAKEUP REMOVER COMPOSITIONSJune 2021January 2024Allow3111NoNo
17331904HAIR TREATMENT COMPOSITIONSMay 2021May 2024Allow3621YesNo
17297238A NASAL SOLUTION WITH CLOSED BASIN NATURAL SPRING WATER CHARACTERISTIC AND METHOD FOR OBTAINING SAID NASAL SOLUTIONMay 2021July 2024Allow3711NoNo
17328992Preventing, treating, and curing illness by denaturing proteins and nucleic acidsMay 2021August 2024Abandon3811YesNo
17235592METHOD OF TREATING AND PREVENTING CORONAVIRUS DISEASE 19 (COVID-19) USING A SELENIUM ADMINISTRATIONApril 2021January 2024Abandon3301NoNo
17286665SLEEP-IMPROVING COMPOSITIONSApril 2021September 2024Abandon4101NoNo
17233031NUTRITIONAL COMPOSITION FOR THE TREATMENT OF METABOLIC DISEASESApril 2021September 2023Allow2910NoNo
17198928USE OF MORCHELLA ACTIVE SUBSTANCEMarch 2021April 2025Abandon4950NoNo
17192185DRUG THERAPY TO INHIBIT CHEMOTHERAPY-INDUCED ADVERSE EFFECTS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING TECHNIQUES AND KITSMarch 2021July 2023Abandon2910NoNo
17188857SYSTEM FOR PROVIDING BIRTH CONTROLMarch 2021April 2023Allow2510NoNo
17267425METHOD OF PREPARING AN ANTIBODY PHARMACEUTICAL FORMULATIONFebruary 2021December 2023Abandon3430NoNo
17265195COMPOSITION CONTAINING A MUCOLYTIC AGENT FOR THE TREATMENT OF MUCUS HYPERSECRETION AND A DEVICE FOR THE DOSING THEREOFFebruary 2021November 2023Allow3421YesNo
17153622NOVEL CHRONOTHERAPY BASED ON CIRCADIAN RHYTHMSJanuary 2021May 2023Abandon2810NoNo
17147692METHOD AND MOLECULAR HYDROGEN-CONTAINING COMPOSITION FOR PROMOTION OF POSTOPERATIVE RECOVERYJanuary 2021February 2024Abandon3730YesNo
17142060COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTSJanuary 2021June 2023Abandon3011YesNo
17126329SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONSDecember 2020October 2022Allow2211NoNo
17120883MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF DIARRHEA AND INFLAMMATION IN THE GASTROINTESTINAL TRACTDecember 2020January 2024Allow3711NoNo
17108081HAIR CONDITIONER COMPOSITIONS CONTAINING BEHENAMIDOPROPYL DIMETHYLAMINEDecember 2020December 2023Allow3630NoNo
17108090HAIR CONDITIONER COMPOSITIONS WITH A PRESERVATIVE SYSTEM CONTAINING SODIUM BENZOATE AND GLYCOLS AND/OR GLYCERYL ESTERSDecember 2020December 2023Allow3630NoNo
17103013FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEMNovember 2020October 2022Allow2310NoNo
17103357PARENTERAL NUTRITION FORMULATIONNovember 2020March 2025Abandon5151NoNo
16950189Medication for Alleviating Parkinson's Symptoms and Method of AdministeringNovember 2020June 2022Abandon1911NoNo
17055150PERSONAL CLEANSING SOAP BAR COMPOSITIONNovember 2020February 2024Allow3911NoNo
17087829MOSQUITO CONTROL AEROSOL AND MOSQUITO CONTROL METHODNovember 2020November 2022Abandon2410NoNo
17082698PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCINOctober 2020October 2022Allow2330YesYes
17050875NEW SALT OF CYSTEAMINE FOR THE PREPARATION OF HIGHLY RESPIRABLE PARTICLESOctober 2020January 2023Allow2601NoNo
17048483A PHARMACEUTICAL DRY POWDER COMPOSITION FOR INHALATION COMPRISING A THYROID HORMONEOctober 2020July 2023Allow3230YesNo
17065818TOPICAL CANNABIDIOL COMPOSITIONOctober 2020January 2024Allow3941YesNo
17041300LIQUID LIPID COMPOSITE COMPOSITION FOR IMPROVING HAIR CONDITIONSeptember 2020November 2023Allow3811YesNo
17009275METHODS AND COMPOSITIONS FOR TREATING HEART CONDITIONSSeptember 2020September 2021Allow1321YesNo
16995388SYSTEM FOR PROVIDING BIRTH CONTROLAugust 2020August 2022Allow2410NoNo
16993503ENCAPSULATED ADIPOSE-DERIVED STEM CELLS, METHODS FOR PREPARATION AND THERAPUTIC USEAugust 2020June 2022Allow2210NoNo
16944614ULTRAVIOLET BLOCKING AGENT AND COSMETIC PRODUCTJuly 2020March 2022Allow1910NoNo
16941413NON-AQUEOUS PATCH FOR THE RELIEF OF PAINJuly 2020June 2023Allow3520YesNo
16931630FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEMJuly 2020June 2022Allow2310YesNo
16946941METHOD OF CONVERTING ATRIAL FIBRILLATION TO NORMAL SINUS RHYTHM AND LOADING ORAL SOTALOL IN A SHORTENED TIME FRAMEJuly 2020March 2022Allow2110NoNo
16961392NEW AGROCHEMICAL FORMULATIONSJuly 2020December 2024Allow5331NoNo
16919415PERSONAL CARE CLEANING COMPOSITIONSJuly 2020August 2023Allow3810YesNo
16959368Stable Liquid Compositions of MelphalanJune 2020February 2023Abandon3201NoNo
16911589ANTIMICROBIAL LATEX OR RUBBER PRODUCTS MADE USING A (NANO)COMPOSITE ZINC OXIDE, AND COMPOSITIONS AND METHODS FOR MAKING SUCH PRODUCTSJune 2020December 2021Abandon1820YesNo
16901909NOVEL ANTIARRHYTHMIC FORMULATIONJune 2020March 2021Allow910YesNo
16901941ANTIARRHYTHMIC FORMULATIONJune 2020March 2021Allow910YesNo
16853905MOSQUITO ATTRACTANT FORMULATIONS AND USES THEREOFApril 2020December 2022Allow3211YesNo
16851096ATTRACTANT OF LADYBUGS, APHID'S NATURAL ENEMYApril 2020January 2021Allow910YesNo
16849099INTRAVENOUS SOTALOL HYDROCHLORIDE LOADING AND MAINTENANCE FOR CARDIAC SURGERY PATIENTSApril 2020August 2021Abandon1620NoNo
16842939SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONSApril 2020September 2020Allow510NoNo
16827388SYSTEM FOR PROVIDING BIRTH CONTROLMarch 2020December 2020Allow910NoNo
16824111COMPOSITION FOR TREATING OR PREVENTING METABOLIC DISEASE, CONTAINING, AS ACTIVE INGREDIENT, EXTRACELLULAR VESICLES DERIVED FROM AKKERMANSIA MUCINIPHILA BACTERIAMarch 2020December 2021Allow2130NoNo
16819290Method for Unlocking Bioactive ProteinsMarch 2020March 2021Allow1210NoNo
16814724SYSTEM FOR PROVIDING BIRTH CONTROLMarch 2020December 2020Allow910YesNo
16801961MDI RELATED PRODUCTS AND METHODS OF USEFebruary 2020August 2022Abandon3040NoNo
16640359DURABLE PEST-REPELLING FORMULATIONSFebruary 2020February 2023Allow3611NoNo
16780226AFFINITY BASED DRUG RELEASE FORMULATIONSFebruary 2020February 2023Allow3611YesNo
16731889HAIR AND SCALP NUTRITION FOR PSORIASIS AND ECZEMADecember 2019July 2022Abandon3001NoNo
16727906COMPOSITIONS, DISPENSING SYSTEMS AND METHODS FOR PROVIDING SENSORIAL AND AESTHETIC BENEFITS TO ACNE PRONE SKINDecember 2019May 2024Abandon5341NoNo
16616904RINSE-OFF CONDITIONER COMPOSITIONS COMPRISING MICROCAPSULESNovember 2019October 2023Allow4741YesNo
16690379Intramammary Veterinary CompositionNovember 2019September 2023Abandon4621NoNo
16690784WOUND DRESSING MATERIALS INCORPORATING ANTHOCYANINS DERIVED FROM FRUIT OR VEGETABLE SOURCESNovember 2019December 2023Abandon4830NoNo
16676618ROACH GEL FORMULATIONSNovember 2019February 2024Allow5150YesNo
16663173MULTI-STAGE BIODEGRADABLE DRUG DELIVERY PLATFORMOctober 2019December 2023Allow5050NoNo
16587833TOPICAL PHARMACEUTICAL COMPOSITIONSSeptember 2019January 2023Allow4040NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NGUYEN, JOHN P.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
15
Examiner Affirmed
15
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.1%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
54
Allowed After Appeal Filing
6
(11.1%)
Not Allowed After Appeal Filing
48
(88.9%)
Filing Benefit Percentile
11.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 11.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner NGUYEN, JOHN P - Prosecution Strategy Guide

Executive Summary

Examiner NGUYEN, JOHN P works in Art Unit 1619 and has examined 418 patent applications in our dataset. With an allowance rate of 44.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner NGUYEN, JOHN P's allowance rate of 44.3% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by NGUYEN, JOHN P receive 2.60 office actions before reaching final disposition. This places the examiner in the 88% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by NGUYEN, JOHN P is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +39.8% benefit to allowance rate for applications examined by NGUYEN, JOHN P. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 14.5% of applications are subsequently allowed. This success rate is in the 5% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 20.3% of cases where such amendments are filed. This entry rate is in the 17% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 75.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 58% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 58.3% of appeals filed. This is in the 27% percentile among all examiners. Of these withdrawals, 57.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 63.0% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.0% of allowed cases (in the 68% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.